Evaluation of the Therapeutic Potential of Garcinia cambogia Alone or in Combination With Silodosin in the Management of LUTS/BPH: A Prospective Randomized Controlled Study

IF 2.1 3区医学 Q2 UROLOGY & NEPHROLOGY

Urology Pub Date : 2025-06-01 DOI:10.1016/j.urology.2025.04.012

Waleed El-Shaer , Adel RA Abd-Allah , Mohamed F. El-Shafie , Ismael M. Salama , Alaa El Shaer

{"title":"Evaluation of the Therapeutic Potential of Garcinia cambogia Alone or in Combination With Silodosin in the Management of LUTS/BPH: A Prospective Randomized Controlled Study","authors":"Waleed El-Shaer , Adel RA Abd-Allah , Mohamed F. El-Shafie , Ismael M. Salama , Alaa El Shaer","doi":"10.1016/j.urology.2025.04.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy of <em>Garcinia cambogia</em> (hydroxy citric acid) alone or in combination with Silodosin on the clinical outcomes of lower urinary tract symptoms/Benign prostatic hyperplasia (LUTS/BPH).</div></div><div><h3>Methods</h3><div>A prospective, randomized, controlled, double-blind study conducted on patients with LUTS/BPH. Eligible patients were assigned randomly to one of three groups. Group <strong>A</strong> (33 patients) received Silodosin, 8 mg, once daily. Group <strong>B</strong> (35 patients) received <em>Garcinia</em> extract 500 mg TID. Group <strong>C</strong> (36 patients) received the combination of Silodosin, plus <em>Garcinia</em> extract. All participants were assessed for the changes in; the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), Post-Void Residual (PVR), prostate volume (PV), and serum Prostatic Specific Antigen (PSA) levels, at the baseline and after 12 weeks of treatment.</div></div><div><h3>Results</h3><div>The baseline data regarding Qmax, IPSS, PVR, PV, and PSA showed non-significant differences between the three groups. After 12 weeks of treatment, all groups showed a significant improvement in both Qmax and IPSS (<em>P</em> >.001) and group C showed the best improvement. The PVR was significantly reduced in all groups (<em>P</em> >.001). The PV was significantly increased in group A (<em>P</em> = .006), whereas it was significantly reduced in groups B and C (<em>P</em> >.001). The PSA showed a non-significant increase in group A (<em>P</em> = .625), while it was significantly decreased in groups B and C (<em>P</em> >.001).</div></div><div><h3>Conclusion</h3><div>Treatment with <em>Garcinia</em> extract, especially in combination with Silodosin, may improve the Qmax, IPSS, PVR, PV, and PSA in patients with LUTS/BPH without any clinical significant adverse effects.</div></div>","PeriodicalId":23415,"journal":{"name":"Urology","volume":"200 ","pages":"Pages 198-205"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090429525003334","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To evaluate the efficacy of Garcinia cambogia (hydroxy citric acid) alone or in combination with Silodosin on the clinical outcomes of lower urinary tract symptoms/Benign prostatic hyperplasia (LUTS/BPH).

Methods

A prospective, randomized, controlled, double-blind study conducted on patients with LUTS/BPH. Eligible patients were assigned randomly to one of three groups. Group A (33 patients) received Silodosin, 8 mg, once daily. Group B (35 patients) received Garcinia extract 500 mg TID. Group C (36 patients) received the combination of Silodosin, plus Garcinia extract. All participants were assessed for the changes in; the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), Post-Void Residual (PVR), prostate volume (PV), and serum Prostatic Specific Antigen (PSA) levels, at the baseline and after 12 weeks of treatment.

Results

The baseline data regarding Qmax, IPSS, PVR, PV, and PSA showed non-significant differences between the three groups. After 12 weeks of treatment, all groups showed a significant improvement in both Qmax and IPSS (P >.001) and group C showed the best improvement. The PVR was significantly reduced in all groups (P >.001). The PV was significantly increased in group A (P = .006), whereas it was significantly reduced in groups B and C (P >.001). The PSA showed a non-significant increase in group A (P = .625), while it was significantly decreased in groups B and C (P >.001).

Conclusion

Treatment with Garcinia extract, especially in combination with Silodosin, may improve the Qmax, IPSS, PVR, PV, and PSA in patients with LUTS/BPH without any clinical significant adverse effects.

查看原文本刊更多论文

评价藤黄果单用或联合西洛多辛治疗LUTS/BPH的治疗潜力：一项前瞻性随机对照研究。

目的：评价藤黄果（羟基柠檬酸）单用或联合西洛多辛治疗下尿路症状/良性前列腺增生（LUTS/BPH）的临床疗效。方法：对LUTS/BPH患者进行前瞻性、随机、对照、双盲研究。符合条件的患者被随机分为三组。A组（33例）给予西洛多辛8 mg，每日1次。B组（35例）给予藤黄提取物500mg TID。C组（36例）采用西洛多辛联合藤黄提取物治疗。对所有参与者的变化进行评估；基线和治疗12周后的最大尿流率（Qmax）、国际前列腺症状评分（IPSS）、空后残留（PVR）、前列腺体积（PV）和血清前列腺特异性抗原（PSA）水平。结果：三组间Qmax、IPSS、PVR、PV、PSA基线数据差异无统计学意义。治疗12周后，各组患者Qmax和IPSS均有显著改善（P < 0.001），其中C组改善效果最好。各组PVR均显著降低（P < 0.001）。A组PV显著升高（P = 0.006）， B、C组PV显著降低（P = 0.001）。a组PSA升高无统计学意义（P = 0.625）， B、C组PSA明显降低（P = 0.001）。结论：用藤黄提取物治疗LUTS/BPH患者，特别是联合西洛多辛治疗可改善Qmax、IPSS、PVR、PV和PSA，无明显临床不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urology 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

9.50%

发文量

716

审稿时长

59 days

期刊介绍： Urology is a monthly, peer–reviewed journal primarily for urologists, residents, interns, nephrologists, and other specialists interested in urology The mission of Urology®, the "Gold Journal," is to provide practical, timely, and relevant clinical and basic science information to physicians and researchers practicing the art of urology worldwide. Urology® publishes original articles relating to adult and pediatric clinical urology as well as to clinical and basic science research. Topics in Urology® include pediatrics, surgical oncology, radiology, pathology, erectile dysfunction, infertility, incontinence, transplantation, endourology, andrology, female urology, reconstructive surgery, and medical oncology, as well as relevant basic science issues. Special features include rapid communication of important timely issues, surgeon''s workshops, interesting case reports, surgical techniques, clinical and basic science review articles, guest editorials, letters to the editor, book reviews, and historical articles in urology.